[Public Notice+] Medipron "Q1 Sales 8.6 Billion KRW... Thanks to Focus on IT Distribution Market"

[Asia Economy Reporter Hyunseok Yoo] Mediphron Divity, a biopharmaceutical company developing new drugs, reported first-quarter sales of 8.6 billion KRW, a 63.7% increase compared to the same period last year. Operating loss for the same period was 250 million KRW.

Mediphron attributed the first-quarter sales growth to the spread of untact (contactless) culture. The IT distribution market is rapidly growing centered on online distribution channels. In particular, Coupang's growth is steep because Gatekeeper, which supplies Logitech products to Coupang, is Mediphron.

A company representative said, “By anticipating changes in the IT distribution market and focusing ahead on online IT distribution markets like Coupang, we achieved record-breaking quarterly results,” adding, “We expect this trend to continue into the second quarter.”

Since Brain Contents became the largest shareholder earlier this year, Mediphron has been accelerating new drug development. In April and May, the company successfully completed consecutive third-party allotment capital increases targeting the largest shareholder and related parties, securing over 25 billion KRW in cash assets.

Mediphron CEO Jang Daeyong said, “Along with growth in the IT distribution business division, we will do our best to become a ‘new drug development bio company with solid fundamentals’ by expanding additional sales in the new drug business division and promoting the commercialization of dementia diagnostic kits within this year to turn profitable.”

Meanwhile, on the 7th, Mediphron successfully completed an equity investment in 'NewMace,' the world’s first developer of diagnostic and therapeutic agents for arteriosclerosis, to secure a new pipeline.

This content was produced with the assistance of AI translation services.